The FDA this month rejected the citizen's petition filed six years ago by the Pharmacists Planning Service to make print size on direct-to-consumer advertising bigger. "We believe that the Food Drug & Cosmetic Act, the implementing regulations, published guidance and the availability of comment and advice from FDA provide sufficient and appropriate direction and flexibility for manufacturers to prepare DTC prescription drug brief summary materials that are readable and legible," FDA Center for Drug Evaluation and Research Director Dr. Janet Woodcock said. PPSI said it is determined to continue its push for larger print.

Full Story:

Related Summaries